PCM
RGLS

Prelude Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Prelude Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,100
Closed -$25.2K – 1497
2024
Q2 		$25.2K Sell
14,100
-118,370
-89% -$275K ﹤0.01% 1171
2024
Q1 		$382K Buy
132,470
+92,210
+229% +$150K 0.02% 766
2023
Q4 		$51.5K Hold
40,260
– – ﹤0.01% 1073
2023
Q3 		$55.2K Sell
40,260
-400
-1% -$580 ﹤0.01% 1040
2023
Q2 		$59.8K Buy
+40,660
New +$54.2K ﹤0.01% 964
2016
Q2 		– Sell
-6
Closed -$5K – 1710
2016
Q1 		$5K Buy
+6
New +$4.77K ﹤0.01% 1199
2015
Q3 		– Sell
-2
Closed -$2K – 1733
2015
Q2 		$2K Buy
+2
New +$3.23K ﹤0.01% 1645

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Prelude Capital Management's RGLS Position: Q3 2024 in Review

Prelude Capital Management sold out of Regulus Therapeutics (RGLS) in Q3 2024, closing a stake of 14,100 shares — an estimated $25.2K sold.

Prelude Capital Management first reported a position in RGLS in Q2 2015 and held it in 7 quarters. The position peaked at $382K in Q1 2024. 70 funds tracked by Wall St. Rank hold RGLS as of Q3 2024.

  • Prelude Capital Management reported no remaining Regulus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Prelude Capital Management sold 14,100 Regulus Therapeutics shares in Q3 2024, an estimated $25.2K.
  • Prelude Capital Management first reported a position in Regulus Therapeutics in Q2 2015 and held it in 7 quarters.
  • Prelude Capital Management's Regulus Therapeutics position peaked at $382K in Q1 2024.
  • 70 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.